Jake Hays

Jake Hays

Associate
Jake Hays
New York
+1 212 459 7111

Jake Hays is an associate in the firm’s Business Law Department and a member of its Technology and Life Sciences groups. His practice focuses on general corporate representation, venture capital financings, mergers and acquisitions, and public offerings. He counsels emerging growth companies at all stages of maturity, including formation, initial funding, expansion, and exit. Mr. Hays represents both private and public companies across a broad range of industries, including biotechnology and diagnostics, AI, Edtech, Fintech, Medtech, e-commerce, retail and consumer products, media and entertainment, consumer and enterprise software, cannabis, and alternative energy and other clean technologies.

Representative Matters

  • Sionna Therapeutics in its $111 million Series B financing
  • Vedere Bio II in its $77 million Series A financing
  • Triplet Therapeutics in its $49 million Series A financing
  • Quentis Therapeutics in its $48 million Series A financing
  • Cadent Therapeutics in its $40 million Series B financing
  • Petfolk in its $40 million Series A financing
  • Hodinkee in its $40 million Series B financing
  • LeafLink in its $35 million Series B financing
  • Alto Solutions in its $17 million Series A financing and $40 million Series B financing
  • Noodle Partners in its $16 million Series B financing and $50 million Series C financing
  • Paperless Post in its Series E financing
  • Bessemer Venture Partners’ investment in Papaya’s $50 million Series B financing
  • Two Sigma Ventures’ investment in Remote Technology’s $11 million Series Seed financing
  • Digital+ Partners’ investment in ChartIQ’s $17 million Series B financing
  • Batu Capital Investments’ investment in MJ Freeway’s $10 million Series C financing

  • LaSalle Hotel Properties in a $5.2 billion merger with Pebblebrook Hotel Trust
  • TripleLift in its $1.4 billion acquisition by Vista Equity Partners
  • Kensho Technologies in its $550 million acquisition by S&P Global
  • Lennar Corporation in the sale of its SunStreet solar platform to Sunnova Energy
  • Johnson & Johnson in the sale of its BabyCenter business to Everyday Health Group
  • TARA Biosystems in its acquisition by Valo Health
  • Plug Power in its $58 million acquisition of Giner ELX, Inc.
  • Plug Power in its $65 million acquisition of United Hydrogen Group Inc.
  • Vedere Bio in its $280 million acquisition by Novartis
  • OncoImmune in its $425 million acquisition (plus undisclosed milestone payments) by Merck

  • Q32 Bio on its strategic collaboration with Horizon Therapeutics to research, develop and commercialize ADX-914 for the treatment of autoimmune diseases for $55 million in initial consideration and staged development funding, and up to an additional $645 million in potential closing and milestone payments
  • Arrakis in its research collaboration agreement with Amgen on the discovery and development of RNA degrader therapeutics, with an upfront of $75 million and up to several billion dollars in potential milestones and royalties
  • Amathus Therapeutics on its strategic collaboration with Merck to develop novel small molecule therapeutic candidates for neurodegenerative diseases, for an upfront payment and milestone payments associated with the successful development candidates in excess of $500 million per program

  • SpringWorks Therapeutics in its $186.3 million initial public offering
  • Cowen and Company and William Blair as underwriters in a $32.5 million follow-on offering for Ovid Therapeutics Inc.
  • Oppenheimer & Co. as underwriters in a $15.4 million follow-on public offering for BioLineRx, Inc.
  • Stifel, Nicolaus & Company as underwriters in a $11.5 million follow-on public offering for IRIDEX Corporation

Professional Activities

Mr. Hays serves as the New York Co-Chair of Goodwin’s Neighborhood Business Initiative (NBI), a program created to provide pro bono legal services to low-income entrepreneurs and small business owners in underserved communities.

Mr. Hays is a member of the Board of Directors of the scientific research institute PSE Healthy Energy (Physicians, Scientists & Engineers) and a member of the Board of Directors of Artists with Evidence, a nonprofit that commissions artists and scientists to collaborate, explore and exhibit art works.

Professional Experience

Prior to joining Goodwin, Mr. Hays served as the Director of the Environmental Health Program at PSE Healthy Energy and as a research associate at Weill Cornell Medicine.

Credentials

Education

JD2017

Fordham University School of Law

(magna cum laude and Order of the Coif)

MA2011

University of Montana

BA2006

Connecticut College

(cum laude)

Admissions

Bars

  • New York

Recognition & Awards

While in law school, Mr. Hays served as the senior articles editor for the Fordham Environmental Law Review, for which he authored Feeling the Noise: Proposed Standards and Alternatives to Wind Energy Nuisance Litigation, 28 Fordham Envtl. L. Rev. 242 (2017). Mr. Hays was chosen as a Stein Scholar for his efforts in public service and received the Adele Monaco Memorial Award, the Archibald R. Murray Public Service Award and the Public Service Student Leadership Award.